[(3S,8R,9S,10S,13S,14S,17R)-10,13-dimethyl-3-sulfooxy-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl] hydrogen sulfate

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: [(3S,8R,9S,10S,13S,14S,17R)-10,13-dimethyl-3-sulfooxy-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl] hydrogen sulfate
• 化学式: C₁₉H₃₂O₈S₂
• 分子量: 452.6
• InChiKey: JHFAETDERBWUOO-LLYHBOAGSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  29
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  144
• 氢给体数：
  2
• 氢受体数：
  8

文献信息

• BIOMARKERS RELATED TO INSULIN RESISTANCE PROGRESSION AND METHODS USING THE SAME
  申请人：Metabolon, Inc.

  公开号：EP2951313B1

  公开（公告）日：2018-03-07
• [EN] BIOMARKERS RELATED TO INSULIN RESISTANCE PROGRESSION AND METHODS USING THE SAME<br/>[FR] BIOMARQUEURS ASSOCIÉS À LA PROGRESSION DE L'INSULINORÉSISTANCE ET PROCÉDÉS D'UTILISATION ASSOCIÉS
  申请人：METABOLON INC

  公开号：WO2014120449A1

  公开（公告）日：2014-08-07

  Biomarkers relating to insulin resistance and insulin resistance-related disorders are provided, as well as methods for using such biomarkers as biomarkers for insulin resistance, dysglycemia, type-2 diabetes, and cardiovascular disease. In addition, methods for monitoring the respective disorders or conditions of a subject are also provided. Also provided are suites of small molecule entities as biomarkers for insulin resistance, dysglycemia, type-2 diabetes, and cardiovascular disease.